Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Oncimmune EarlyCDT Lung

Biodesix has commercially launched Oncimmune's EarlyCDT Lung test in the US, under a commercialization agreement the two firms announced last year. Marketed under Biodesix's Nodify Lung brand, the new Nodify CDT test is designed to assist physicians to identify patients with lung nodules at high risk of lung cancer.

The assay joins Biodesix's existing Notify XL2 test for low-risk lung nodule detection, and, according to Oncimmune, both tests will now be offered together as the Nodify Lung Nodule Risk Assessment strategy, with physicians able to order the two assays from a single blood draw.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.